Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors

NCT04064359 is registered in ClinicalTrials.gov with Oxford BioTherapeutics Ltd as lead sponsor.

NCT NCT04064359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04064359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors
Lead sponsor
Oxford BioTherapeutics Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
July 25, 2019
Completion date
December 31, 2027
Enrollment
200 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor